Long-term treatment of patients with HIV-1: the role of atazanavir

Miguel Ángel Artacho¹
Pablo Barreiro²
José Vicente Fernández-Montero²

¹Department of Internal Medicine, Hospital Universitario Gregorio Marañón, Madrid, Spain; ²Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain

Background: The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better tolerance and convenience has been achieved in recent years.

Objective: To summarize and update evidence-based information about atazanavir (ATV) on initial, simplification, and rescue interventions in HIV patients.

Methods: Review of observational and randomized trials reported in medical conferences, peer-reviewed journals, and treatment guidelines.

Results: ATV is a second-generation PI, which has shown across studies potent antiviral activity and high genetic barrier, both in HAART-naïve patients or after virological failure. Indulgent metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the long-term management of HIV infection.

Keywords: atazanavir, HAART, protease inhibitors

Introduction

The availability of protease inhibitors (PI) has dramatically changed the natural history and treatment of HIV infection. This drug class became available in the mid 90s and allowed for the first time, as part of triple combinations, sustained suppression of HIV replication followed by immune restoration and prolonged AIDS-free survival. Nevertheless, first-generation PI have some disadvantages as compared with other drug classes later developed, such as non-nucleoside reverse transcriptase inhibitors (NNRTI) or integrase inhibitors (INSTI).¹ PI require pharmacokinetic enhancement with ritonavir (RTV) to ensure potency and facilitate adherence. Low doses of RTV potentially inhibit several cytochrome P450 isoenzymes, mainly CYP3A4, which are critical for the gastrointestinal and liver clearance of other PI. The net effect is greater plasma concentrations of the active PI, which allows twice or once daily dosing and significant reductions in pill burden. Poor gastrointestinal tolerance, metabolic abnormalities, and fat redistribution still penalize long-term use of first-generation PI.

Newer PI have been developed to overcome some of the limitations of older PI. Among these, ATV, marketed as Reyataz® (Bristol-Myers Squibb) since 2003, should be highlighted for its favorable lipid profile, once-daily dosing, low pill burden, and high genetic barrier to resistance. Furthermore, ATV may be administered without RTV enhancement or, when needed, at low doses not usually related with significant adverse effects.

Correspondence: José Vicente Fernández-Montero
Department of Infectious Diseases,
Hospital Carlos III, C/Sinesio Delgado 10,
28029 Madrid, Spain
Tel +34 91 4532500
Fax +34 91 7336614
Email jvicfer@gmail.com

Pharmacology and pharmacokinetics of ATV

ATV is an azapeptide inhibitor of the HIV-1 protease, with following chemical name: (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentazatetradecanedioic acid dimethyl ester sulfate (Figure 1). The compound inhibits the virus-specific processing of viral *Gag* and *Gag-Pol* polyproteins of HIV-1 group M, subtypes A, B, C, D, AE, AG, F, G, and J, in infected cells thus preventing formation of mature virions.²

In some studies on PI-naïve patients,^{3,4} the concentration that inhibits 50% of viral replication (IC₅₀) in the absence of human serum, ranged from 0.6 ng/mL to 5.7 ng/mL. The presence of 40% human serum in cell cultures increased ATV IC₅₀ by 2.7- to 3.6-fold, as found with other PIs. The adjusted IC₅₀ for protein binding was estimated to range from 8 to 20 ng/mL against reference viral strains with a conventional cycle cell infection and the PhenoSense™ single assay (ViroLogic, Inc, South San Francisco, CA, USA), respectively.³

ATV is rapidly absorbed with a C_{max} occurring after approximately 2.5 h post-dosing, demonstrating non-linear pharmacokinetics, a feature that allows once daily posology^{5,6} (Table 1). The extent of absorption is highly dependent on gastric pH and increases when taken together with food. ATV is highly bound to human serum proteins (up to 86%), especially and in a similar proportion to alpha-1-acid glycoprotein and albumin. ATV is a substrate for P-glycoprotein (P-gp), an efflux transporter that will act to limit tissue compartment

distribution. Like other PIs, ATV is extensively metabolized by the hepatic cytochrome P450, primarily by the CYP3A4 and CYP3A5 isoenzymes. ATV metabolites follow biliary and urinary excretion for 79% and 13% of the administered dose, respectively. Unchanged drug is found in feces and urine in proportions of 20% and 7% of the dose administered, respectively. Steady-state is achieved after 4 to 8 days of treatment, with a body accumulation of approximately 2.3-fold. Finally, ATV enters scarcely the cerebrospinal or semen compartments, although improves with RTV boosting.⁷

Addition of RTV at low doses (100 mg daily) to ATV at slightly lower doses (300 mg daily) results in an increase of ATV half-life, minimum (C_{min}) and maximum concentrations (C_{max}), and area under the curve (AUC) as compared with ATV 400 mg daily alone. A study involving 214 HIV-infected patients⁸ showed a large inter-individual variability in ATV disposition, which was associated with factors like prior exposure to RTV or nevirapine (NVP), as well as body weight.

There are scarce data on the use of ATV in pediatric patients and the optimal dosage has not been established. The phase I/II PATCG 1020A trial, involving 172 HIV-infected children with an age range of 1 to 17 years, studied ATV at a dose of 310 mg per m² of body surface, adjusted over 24 hours. AUC values showed great variability, which was particularly evident between younger and older patients.⁹

Although liver safety of ATV is proven, pharmacokinetics in patients with hepatic impairment remains an important issue given major liver metabolism of the drug. Though there are few data of ATV use in HIV-infected patients with severe

Figure 1 Chemical structure of atazanavir sulfate.

Table 1 Pharmacokinetic parameters at steady state after atazanavir (ATV) 400 mg once daily and after atazanavir (ATV) 300 mg with ritonavir 100 mg once daily with a light meal in HIV-infected patients²

	ATV 400 mg	ATV/RTV 300/100 mg
Bioavailability (%)	68	Not available
Protein binding (%)	86	86
Cl _h (L/h)	25.2	Not available
Cl _r of parent drug (%)	7	Not available
t _{1/2} , mean ± SD (h)	6.5 ± 2.6	8.6 ± 2.3
C _{max} , mean ± SD (ng/mL)	3152 ± 2231	5233 ± 3033
T _{max} , median (h)	2	3
C _{min} , mean ± SD (ng/mL)	273 ± 298	862 ± 838
AUC, mean ± SD (ng/mLh)	22262 ± 20159	53761 ± 35294

hepatic dysfunction, an increased exposure to ATV should be expected. In pharmacokinetic studies carried out in non-infected adults with moderate to severe hepatic impairment, AUC was increased in 42% after a single dose of ATV of 400 mg, compared with healthy volunteers. On the basis on these data, a dose reduction of ATV is advised for patients with moderate hepatic dysfunction. In contrast, in a study conducted in 58 HCV/HIV-coinfected patients with compensated liver disease, ATV C_{min} did not differ significantly between patients with and without cirrhosis.¹⁰

ATV pharmacokinetics has also been studied in patients with renal impairment. Doses of ATV of 400 mg QD have been assessed in 20 adults with severe renal impairment, including a few in hemodialysis. The mean ATV C_{max} was 9% lower, AUC was 19% higher, and C_{min} was 96% higher in subjects with severe renal impairment not undergoing hemodialysis, than in subjects with normal renal function. When ATV was administered either prior to or following hemodialysis, the geometric means for C_{max}, AUC, and C_{min} were approximately 25% to 43% lower compared to subjects with normal renal function. No dose adjustment is required in patients who are not undergoing hemodialysis, and such patients should receive the standard dose of 300 mg per day of ATV with 100 mg per day of RTV. ATV should not be administered in patients with end stage renal disease managed with hemodialysis.²

Some pharmacokinetic studies in pregnant women are available. In 12 HIV-infected women receiving boosted ATV¹¹ the AUC and C_{min} in third trimester of pregnancy were approximately 40 and 21% lower, respectively, than in non-pregnant HIV-infected women. All individuals reaching delivery achieved plasma HIV-RNA < 50 copies/mL and all infants tested were HIV-negative and presented normal bilirubin levels through day 14. Nevertheless, one newborn

developed grade 3 hyperbilirubinemia at day 15. In another study,¹² total bilirubin concentrations in newborns were above normal limits at birth and day 3, and three neonates had transient jaundice which did not require phototherapy. Data obtained in trials assessing other PI in pregnant women¹³ suggest a decrease in plasma exposure during the third trimester. Current guidelines¹⁴ consider ATV as an alternative regimen to first-line choice with lopinavir (LPV). No evidence of human teratogenicity has been communicated to date. Furthermore, ATV transplacental passage is low which favors fetal safety but may compromise vertical prophylaxis. The recommended dosage of ATV during pregnancy is 300 mg QD, with 100 mg of RTV. ATV plasma concentrations should be monitored throughout the pregnancy period to ensure levels greater than 150 ng/mL, although no dose adjustment has yet been established.

ATV is a substrate and inhibitor of CYP3A, CYP2C8, UGT1A1, and P-gp.¹⁵ Therefore, administration of ATV and drugs primarily metabolized by these isoenzymes and/or substrates of P-gp may cause an increase in plasma concentrations of the concomitant drug, potentially enhancing or prolonging both their therapeutic and adverse effects. Due to afore mentioned inhibitory effect of RTV on CYP3A isoenzyme, the magnitude of drug interaction with boosted ATV may change. Drugs inducing CYP3A4 and/or P-gp metabolism, such as rifampin, may decrease ATV plasma concentrations and therefore compromise ATV therapeutic effect. Finally, drugs altering the gastric pH may affect ATV solubility and consequently its bioavailability. Use of proton pump inhibitors along with ATV should be avoided (Table 2).

Antiviral efficacy

ATV has shown its efficacy both in treatment-naïve and experienced patients, with a high genetic barrier, as found in several studies (Table 3). The Phase II studies BMS-AI424-007 and BMS-AI424-008.^{16,17} The AI424-034 study¹⁸ compared unboosted ATV (400 mg daily) with EFV in combination with zidovudine (AZT) plus lamivudine (3TC) as the nucleoside backbone. Probably due to recruitment of a significant number of patients with high plasma HIV-RNA concentrations (42% with ≥ 5 log₁₀ copies/mL) and low CD4 counts (median of 282 cells/μL), performance after 48 weeks was lower than expected, although comparable between groups (70% and 64% of patients attained < 400 HIV-RNA copies/mL with ATV and EFV, respectively). Both regimens were also comparable with respect to the magnitude and rate of CD4 T-cell gains. EFV was associated with less favorable outcome

Table 2 Main drug interactions with atazanavir (ATV)¹⁴

Family	Drug	Effect on concentration	Recommendation
Antiarrhythmics	amiodarone, bepridil, lidocaine, quinidine	↑ antiarrhythmic	Caution is warranted, TDM recommended.
Anticoagulants	warfarin	↑ warfarin	Monitoring of INR is recommended.
Anticonvulsants	carbamazepine, phenobarbital, phenytoin	expected ↓ ATV	Use with caution.
Antidepressants	tricyclic antidepressants, trazodone	↑ tricyclic antidepressants, ↑ trazodone	Use with caution, TDM is recommended. TDM is recommended and lower trazodone doses should be used.
Antifungals	itraconazole, ketoconazole	↑ itraconazole, ketoconazole (ATV 400)	If ATV is used with RTV, itraconazole or ketoconazole doses of >200 mg/day should be used with caution.
Antihistamines	astemizole, terfenadine	no data available	ATV/RTV should not be used in combination with drugs that are substrates of the CYP3A4 and have narrow therapeutic windows, such as terfenadine and astemizole.
Antimicrobial agents	clarithromycin	↑ clarithromycin, ↓ 14-OH-clarithromycin, ↑ ATV concentrations	Dose reductions by 50% should be considered. Combination with boosted ATV has not yet been studied.
Antimycobacterials	rifabutin, rifampicin	↑ rifabutin, severe ↓ ATV	Reduce rifabutin dose to 150 mg every other day or to 3x/week. Contraindicated.
Antiretroviral agents	NRTIs: didanosine (buffered formulation), tenofovir	↓ ATV, ↓ didanosine, ↓ ATV, ↑ tenofovir	Didanosine should be administered 1 h before or 2 h after ATV/RTV intake. Avoid combination of tenofovir with unboosted ATV.
	NNRTIs: efavirenz, nevirapine, etravirine	↓ ATV, expected ↓ ATV, ↑ etravirine, ↓ ATV	The recommended dose in treatment-naïve patients is ATV/RTV 300/100 mg. No recommendation has been established in treatment-experienced patients. Coadministration is not recommended. ATV should be boosted with RTV.
	PIs: indinavir, saquinavir (soft gelatin capsules), tipranavir	↑ saquinavir, expected ↓ ATV	Contraindicated due to synergistic effect on hyperbilirubinemia. Appropriate recommendations for this combination have not been established. TDM is recommended. ATV and tipranavir should not be coadministered.
	INSTIs: raltegravir	↑ raltegravir	The clinical relevance of these data is unknown.
	Calcium channel blockers: diltiazem	↑ diltiazem and desacetate-diltiazem	Caution is warranted. 50% dose reduction of diltiazem should be considered.
	felodipine, nifedipine, nicardipine, verapamil	↑ felodipine, nifedipine, nicardipine, verapamil	Caution is warranted and ECG monitoring is recommended. Dose titration should be considered.
	Corticosteroids: fluticasone	↑ fluticasone	Caution is warranted.
	Ergot derivatives: dihydroergotamine, ergotamine, ergonovine, methylethergonovine	↑ ergot derivatives	Contraindicated.
	Acid suppressive therapy: antacids	↓ ATV	ATV should be administered 2 h before or 1 h after intake of antacids.
	H ₂ receptor antagonists	↓ ATV	H ₂ receptor antagonist should not exceed a 40 mg dose equivalent of famotidine twice daily and ATV should be administered with RTV simultaneously, with, and/or at least 10 h after the dose of the H ₂ -receptor antagonist.
	proton pump inhibitors	↓ ATV	ATV/RTV is recommended. Proton-pump inhibitor dose should not exceed a 20 mg dose equivalent of omeprazole and must be taken approximately 12 h prior to ATV/RTV in antiretroviral-naïve patients. Proton-pump inhibitors should not be used in treatment-experienced patients.
Herbal products	worth	expected ↓ ATV	Contraindicated.
HMG-CoA reductase Inhibitors	lovastatin, simvastatin	↑ lovastatin, simvastatin	Contraindicated.

(Continued)

Table 2 (Continued)

Family	Drug	Effect on concentration	Recommendation
	atorvastatin, rosuvastatin	↑ atorvastatin, rosuvastatin	Use the lowest possible dose of atorvastatin or rosuvastatin with careful monitoring or consider other HMG-CoA reductase inhibitor such as pravastatin or fluvastatin.
Immuno-suppressants	cyclosporine A, sirolimus, tacrolimus	↑ immunosuppressants	TDM is recommended.
Neuroleptics	pimozide	↑ pimozide	Contraindicated.
Oral contraceptives	ethinyl estradiol, norethindrone	↓↑ oral contraceptives	Due to possible alteration of oral contraceptive concentrations, alternative/additional contraceptive measures should be used when coadministered with ATV or ATV/RTV.
PDE5 inhibitors	sildenafil, tadalafil, vardenafil	↑ sildenafil, tadalafil, vardenafil	Do not exceed 25 mg of sildenafil in 48 h, 10 mg of tadalafil in 72 h or 2.5 mg of vardenafil in 72 h.

Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase inhibitor; ATV, atazanavir; RTV, ritonavir; TDM, Therapeutic drug monitoring; INR, international normalized ratio; ECG, electrocardiogram.

in lipids (triglycerides and total LDL and HDL cholesterol) as compared with ATV. No significant variations in glucose metabolism were noticed in either group, although patients on EFV tended to show slight increases in fasting insulin levels.

The AI424-089 study,¹⁹ a randomized, multicenter, 96-week study, compared the efficacy and safety of boosted vs unboosted ATV in drug-naïve patients. Although overall efficacy results were comparable, rates of response were higher and emergence of PI resistance mutations lower in subjects on ATV plus RTV than with ATV alone. Concerns on a limited potency of unboosted ATV have been noted in several antiretroviral treatment guidelines, in which ATV alone is only recorded as an alternative option only for PI-naïve patients, or in simplification strategies. Use of tenofovir (TDF) always require boosted ATV due to lower PI exposure, unless ATV plasma levels >150 ng/mL were confirmed under ATV alone.

The CASTLE trial,²⁰ an open-label international non-inferiority study, randomly assigned 883 treatment-naïve patients to receive either boosted ATV or LPV at standard doses, in combination with a fixed dose of tenofovir plus emtricitabine. After 48 weeks, plasma HIV-RNA <50 copies/mL was attained at similar rates in both arms (78% and 76%, respectively) and CD4 gains were also comparable. Serious adverse events occurred in 12% of patients in the ATV group and in 10% of patients in the LPV group. However, a better lipid profile was observed in patients receiving ATV as compared with LPV. Moreover, gastrointestinal side effects were more common in the LPV group, whereas those receiving ATV were more likely to experience jaundice. Both treatments, however, were in general very well tolerated (Figure 2). The 96-weeks²¹ extension analysis confirmed that ATV was superior to LPV in terms of antiviral efficacy. In an intention-to-treat (ITT) analysis, 74% of patients in the ATV arm achieved HIV-RNA <50 copies/mL, compared

Table 3 Different genotypic resistance scores for atazanavir (boosted or unboosted) in relationship to clinical responses

Source	Atazanavir	Protease mutations	Clinical cut-off
Colonna et al ³	Unboosted	L10F/I/V, K20I/M/R, L24I, L33F/I/V, M36I/L/V, M46I/L, G48V, I54L/V, L63P, A71I/V/T, G73A/C/S/T, V82A/F/T/S, I84V, L90M, or the presence of I50L alone	<versus ≥4
ANRS 2004 www.sante.gouv.fr	Boosted	L10F/I/V, K20I/M/R, L24I, L33F/I/V, M36I/L/V, M46I/L, G48V, I54L/V, L63P, A71I/V/T, G73A/C/S/T, V82A/F/T/S, I84V, L90M, or the presence of I50L alone	<versus ≥6
ANRS 2005 ³⁹	Boosted	L10F/I/V, G16E, L33F/I/V, M46I/L, D60E, I84V, I85V, L90M, or the presence of I50L alone	<versus ≥3
Pellegrin et al ⁴⁰	Boosted	L10F/I/V, K20I/M/R, L24I, M46I/L, I54L/V, Q58E, L63P, A71I/V/T, G73A/C/S/T, V77I, V82A/F/T/S, I84V, L90M, or the presence of I50L alone	<versus ≥5
Bertoli et al ⁴¹	Unboosted	L10C/I/V, V32I, E34Q, M46I/L, F53L, I54A/M/V, V82A/F/I/T, I84V, I15E/G/L/V, H69K/M/N/Q/R/T/Y, I72M/T/V	<versus ≥4
Bertoli et al ⁴¹	Boosted	G16E, V32I, K20I/M/R/T/V, L33F/I/V, F53L/Y, I64L/M/V, A71I/T/V, I85V, I93L/M	<versus ≥3

Figure 2 Potency and resistance genetic barrier of distinct protease inhibitors.

with 68% in the LPV group ($P < 0.05$). This superiority was also found when stratifying patients according to high ($>100,000$ copies/mL) or low ($<100,000$ copies/mL) baseline HIV-RNA levels. There were no significant differences among groups when comparing the CD4 cell count increase from baseline to 96 weeks (difference of 221 cells/mL; 95% CI, -43 to 1). Adherence and safety profiles were similar in both groups in the extended analysis. Virological failures due to resistance were scarce and appeared in similar proportions in both groups, 6% and 7% in the ATV and LPV arms, respectively. The overall incidence of Grades 2–4 treatment-related adverse events was 30% and 32% in those patients on the ATV and LPV regimens, respectively. While gastrointestinal side effects were more common in the LPV group, hepatobiliary adverse events, namely jaundice and hyperbilirubinemia, were more frequent in the ATV group. Only 3 patients discontinued ATV therapy due to such events, none of them between weeks 48 and 96.

Altogether these studies support the use of once-daily boosted ATV as a good first-line treatment option.

Recently, the results of ACTG 5202 trial²² have become available. This trial, involving 1,857 HIV treatment-naïve patients, assessed the efficacy of EFV and boosted ATV, combined with either TDF plus FTC or abacavir

(ABC) plus lamivudine (3TC) with a follow-up period of 96 weeks. In terms of time to loss of virological response (TLOVR), no significant differences were found between ATV and EFV regardless nucleoside combination (HR 1.13 [95% CI, 0.82–1.56] with ABC/3TC and HR 1.01 [95% CI, 0.7–1.46] with FTC/TDF). The combination of ABC/3TC plus ATV was associated with a longer time to regimen modification. Drug resistance rate was significantly lower in the ATV group when compared with EFV, regardless of nucleoside combination. ATV showed when combined with TDF/FTC a greater increase in CD4 cell count. Other trials comparing boosted ATV with NVP such as ArTEN²³ and NEwArT as first-line therapy are ongoing.

RTV-boosted ATV has also been assessed as salvage therapy. The AI424-009 study²⁴ was a randomized, multicentre, pilot trial that compared the safety and efficacy of SQV 1,200 mg QD plus ATV 400 mg or 600 mg QD vs RTV boosted SQV 400/400 mg BID. At 48 weeks, the dual PI regimens were as effective and well tolerated as RTV plus SQV. There were fewer discontinuations caused by adverse events in the ATV plus SQV groups (9% and 11%, respectively) than in the RTV plus SQV group (30%). Moreover, ATV groups showed significantly lower increase in lipids as compared with the SQV plus RTV group (1% vs 10% in total

cholesterol, -0.6 vs $+23.2\%$ in LDL-cholesterol, and -4.8 vs $+93\%$ in triglyceride levels).

In the AI424-043 study,²⁵ patients who had failed at least one PI were rescued with unboosted ATV versus boosted LPV. The LPV arm resulted in a significantly greater reduction in plasma HIV-RNA than the ATV arm. Likewise, a greater CD4⁺ T-cell gain was seen with LPV than ATV ($+169$ vs $+112$ cells/ μ L). However, whereas LPV increased lipid levels and induced insulin resistance, these parameters remained stable in the ATV arm.

Finally, the AI424-045 study²⁶ compared boosted ATV with boosted LPV in patients who had failed at least two triple regimens. Approximately 40% of patients harboured ≥ 4 nucleoside-associated resistance mutations and more than one third harboured ≥ 4 PI resistance mutations. In the intention-to-treat analysis at 96 weeks,²⁷ similar virological efficacy was demonstrated for ATV and LPV arms, with 44% vs 46% of patients achieving <400 HIV-RNA copies/mL, respectively. Moreover, CD4 gains were comparable ($+160$ and $+142$ cells/ μ L, respectively). Although response rates were similar when fewer than four PI resistance mutations were present at baseline, LPV was slightly superior to ATV in patients with more than three PI resistance mutations. Conversely, the ATV arm benefited from less frequent gastrointestinal disturbances and significant reductions in total and LDL cholesterol, and triglyceride levels. The main drawback was that grade 3–4 hyperbilirubinemia developed in 53% of patients on ATV.

ATV has also been studied in several simplification trials. In the SLOAT study,²⁸ HIV patients with undetectable plasma HIV-RNA for longer than 24 weeks while under boosted LPV were randomized to continue on the same therapy or switch to boosted (in those on TDF) or unboosted ATV. The rate of virological failures at 48 weeks did not differ between groups. A significant reduction was seen in median total cholesterol and triglycerides in the ATV switch group, whereas no significant changes occurred in the control LPV arm. Greater reductions in total cholesterol and triglycerides were seen in patients switched to unboosted ATV.

The SWAN²⁹ study was a 48-week, open-label, prospective trial involving HIV patients with virologic suppression who were receiving stable PI-based regimens, with or without RTV. Again, patients were randomized 2:1 to boosted or unboosted ATV, depending on TDF use, or to continue on their prior PI. After 48 weeks, patients switched to ATV showed significantly lower total cholesterol, fasting triglycerides, and non-HDL cholesterol than patients in the comparator PI group. For patients with prior exposure to RTV-boosted PI

regimens, the two treatment groups had comparable rates of virologic rebound. In contrast, significantly lower rebound rates were recognized for ATV vs comparator PI groups in the subset of patients with prior exposure to unboosted PI. A limitation of this study was that nearly half of the study participants entered the trial receiving obsolete unboosted PI modalities, and most of them switched to unboosted ATV, which is not the current standard of care.

Finally, boosted ATV has also been assessed as monotherapy. The ACTG 5201 study³⁰ was a prospective pilot trial with 34 HIV adults with virological suppression for ≥ 48 weeks receiving their first PI regimen. All participants switched to boosted ATV at entry and discontinued the nucleoside analogue backbone after 6 weeks. Three participants (9%) experienced virologic failure at weeks 12, 14, and 20 after simplification without emergence of any PI resistance mutation. Plasma ATV concentrations at failure were low or below detection in two out of three subjects. The authors concluded that ATV/r maintenance monotherapy could be a valuable option in a subset of HIV patients, though no predictors of failure were identified.

The ATARITMO study³¹ tried to determine the feasibility of boosted ATV maintenance monotherapy, along with its effects on viral replication, in compartments other than plasma; for example, in the cerebrospinal fluid and semen. At week 24, 3 of 20 patients had detectable viral load in those compartments, despite viral suppression in plasma. As already mentioned, the general perception nowadays is that PI monotherapy must not be considered as an acceptable optional strategy when any other modality of triple antiretroviral regimen can be afforded.

Safety and tolerability

ATV is generally well tolerated, as shown by the fact that only 5%–10% of patients discontinued the drug due to adverse events in the main register trials.¹ Indirect bilirubin elevation is the most frequent side effect reported, which is frequently seen within the first months on ATV therapy and tend to slightly decline thereafter due to metabolic compensation mechanisms. This laboratory abnormality only achieves clinical relevance (grade 3–4) in up to one third of patients across studies. Jaundice is infrequent ($<10\%$) and causes ATV discontinuation very rarely (around 1% of treated patients). Bilirubin levels seem to be directly associated to plasma concentrations of ATV; thus, it is more frequent when the drug is boosted with RTV. Of note, hyperbilirubinemia is completely reversible after stopping ATV. Patients with Gilbert's disease or hemolytic anemia

caused by thalassemia or ribavirin treatment for hepatitis C experience jaundice more frequently when treated with ATV.³² Grade 3–4 elevations in transaminases have been observed in 3%–14% of patients receiving ATV. Liver enzyme elevations do not correlate with increased serum bilirubin, and are more frequently seen in HIV subjects with underlying chronic hepatitis B or C. In the AI424-007 study,¹⁶ in which ATV was given in combination with didanosine and stavudine, grade 3–4 elevations in transaminases occurred in 20% of patients with chronic hepatitis B and in 40% of patients with chronic hepatitis C, but in <10% of HIV-monoinfected individuals. In studies AI424-008¹⁷ and AI424-034,¹⁸ ALT levels >5 times the upper limit of normality were seen respectively in 15%, 14% and 17% of seropositive patients for hepatitis B or C treated with ATV, EFV, and nelfinavir. In study AI424-045,²⁶ 20 patients treated with ATV/RTV and 18 with LPV/RTV, all seropositive for hepatitis B and/or C, experienced increases in ALT levels >5 times the upper limit of normality in 25% and 6% of cases, respectively. Therefore, liver function tests should periodically be monitored in patients on ATV with underlying chronic liver disease.

Patients on ATV may occasionally complain of gastrointestinal disturbances, although symptoms are generally mild. In the AI424-007¹⁷ study, grade 3–4 nausea/vomiting, abdominal pain, or diarrhea occurred in only 2%–3% of patients. Of note, these side effects do not seem to rise when ATV is boosted with RTV. Indeed, in the AI424-045²⁸ the incidence of grade 2–4 gastrointestinal symptoms was 3% in the ATV/RTV arm but was much higher in the LPV/RTV arm (11%).

ATV has been shown to prolong the PR interval in electrocardiograms performed on healthy volunteers as well as in HIV-infected patients.³³ This adversity was not originally reported during the clinical development of the drug and has only rarely been noticed in the post-marketing period.³⁴ Abnormalities in atrioventricular conduction are generally asymptomatic, concentration-dependent and limited to first-degree atrioventricular block. Anecdotal reports of second-degree atrioventricular block and other conduction abnormalities have been published. A retrospective analysis of patients enrolled in the ATV expanded access programme (AI424-900 study³⁵) has shown that QRS intervals increased by a median of 5 ms in 75% of antiretroviral-experienced patients, using either boosted or unboosted ATV. The PR and the QTc intervals did not change significantly. According to pooled data from the manufacturer's prescribing information, the incidence

of QTc interval prolongation in a total of 1,793 patients treated with ATV was comparable to that of patients receiving other PIs, with none of the patients showing a QTc interval >500 ms. An additive effect of ATV and drugs that prolong the PR interval (eg, beta-blockers, verapamil, digoxin) and the QT interval cannot be excluded. Hence, when possible these combinations should be avoided. Though very rare, these findings could support periodically performing electrocardiogram monitoring in patients treated with ATV, particularly when boosted with RTV.

Unlike other PIs, ATV seems to have a favorable metabolic profile, namely regarding lipid abnormalities and insulin resistance.³⁶

Nephrolithiasis has also been rarely related with ATV exposure,³⁷ cause by precipitation of the active principle in the urinary tract. In one retrospective study the prevalence of ATV-associated urolithiasis was 0.97%.³⁸ Patients with low water intake, high urinary pH, and prior history of urinary stones are at higher risk for ATV-associated urine crystallization.

Conclusions

ATV is an antiretroviral drug that provides a well proven antiviral efficacy, high genetic barrier, low daily pill burden, as well as a more friendly metabolic profile than previous PI. Although ATV is one of the most recently developed PI, there is already strong evidence available for allowing the inclusion of ATV in most guidelines as a preferred regimen. DHHS guidelines include once-daily ATV/r as one of the preferred regimens in combination with emtricitabine (FTC) and tenofovir (TDF) as nucleoside analog backbone. ATV/r can also be combined with abacavir (ABC) or zidovudine (AZT) plus lamivudine (3TC), in what has been considered an alternative regimen. Unboosted ATV can be used in combination with ABC or AZT plus 3TC in cases when RTV boosting is not possible. The 2009 European AIDS Clinical Society Guidelines consider ATV/r as a recommended regimen when combined with either FTC plus TDF or ABC plus 3TC.

Available evidence supports the widespread use of ATV as base for HAART regimens both in treatment-naïve or pretreated patients. Though having been available since 2003, there is enough data from lengthy trials confirming ATV as an efficacious antiretroviral, with a high genetic barrier and a rather friendly metabolic profile. Its favorable safety profile, low daily pill burden and the once-daily administration favors a high adherence to ATV-containing HAART regimens, making ATV a very interesting drug for HIV treatment.

Disclosure

The authors declare no conflicts of interest.

References

- Fernandez-Montero JV, Barreiro P, Soriano V. HIV protease inhibitors: recent clinical trials and recommendations on use. *Expert Opin Pharmacother*. 2010;10:1615–1629.
- Bristol-Myers Squibb Company. Princeton, NJ 08543, USA. Reyataz product information. Accessed 15 Apr 2010. Available from: http://packageinserts.bms.com/pi/pi_reyataz.pdf
- Colonna R, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of HIV type 1 clinical isolates resistant to one or more approved protease inhibitors. *Antimicrob Agents Chemother*. 2003;47:1324–1333.
- Drusano G, Bilello J, Preston S, et al. Hollow-fiber unit evaluation of a new HIV type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. *J Infect Dis*. 2001;183:1126–1129.
- O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects. 7th Conference on Retrovirus and Opportunistic Infections. Jan 3 – Feb 4, 2000. San Francisco, CA, (Abstract 504).
- McCabe SM, Ma Q, Shish JC, et al. Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment. *Clin Pharmacokinet*. 2008;47(3):153–172.
- Rivas P, Morello J, Garrido C, Rodríguez-Nóvoa S, Soriano V. Role of atazanavir in the treatment of HIV infection. *Ther Clin Risk Manag*. 2009;5:1–18.
- Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with HIV infection. *Antimicrob Agents Chemother*. 2006;50:3801–3808.
- Rutstein R, Samson P, Kiser J, et al. The PATCG 1020 protocol: Atazanavir with or without ritonavir in HIV-infected infants, children, and adolescents. 14th Conference on Retroviruses and Opportunistic Infections. Feb 3–5, 2007. Los Angeles, CA (Abstract 715).
- Barreiro P, Rodríguez-Novoa S, Labarga P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. *J Infect Dis*. 2007;195:973–979.
- Eley T, Vandeloise E, Child M, et al. Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300 mg once daily/Ritonavir 100 mg once daily + ZDV/3TC during the third trimester in HIV+ women. 15th Conference on Retroviruses and Opportunistic Infections. Feb 3–6, 2008. Boston, MA (Abstract 624).
- Ferreira C, Floch-Tudal C, Meier F, et al. Atazanavir in pregnancy: Influence on neonatal hyperbilirubinemia. 15th Conference on Retroviruses and Opportunistic Infections. Feb 3–6, 2008. Boston, MA (Abstract 625).
- Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. *Clin Pharmacokinet*. 2004;43:1071–1087.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Dec 1, 2009;1–161. Accessed Apr 5, 2010. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>
- Perloff E, Duan S, Skolnik P, et al. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. *Drug Metab Dispos*. 2005;33:764–770.
- Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. *J Acquir Immune Defic Syndr*. 2003;32:18–29.
- Murphy R, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. *AIDS*. 2003;17:2603–2614.
- Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose ZDV and lamivudine, as initial therapy for patients infected with HIV. *J Acquir Immune Defic Syndr*. 2004;36:1011–1019.
- Malan D, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naïve patients. *J Acquir Immune Defic Syndr*. 2008;47:161–167.
- Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. *Lancet*. 2008;372:646–655.
- Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. *J Acquir Immune Defic Syndr*. 2010;53:323–332.
- Daar ES, Tierney C, Fischl M, et al. ACTG 5202: Final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naïve HIV-infected patients. 17th Conference on Retrovirus and Opportunistic Infections. Feb 16–19, 2010. San Francisco, CA. (Abstract 59LB).
- Soriano V, de Rossi L. A review of the atazanavir, ritonavir, tenofovir, emtricitabine and nevirapine trial. *Eur Infect Dis*. 2010. (In press).
- Haas D, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. *AIDS*. 2003;17:1339–1349.
- Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. *Curr Med Res Opin*. 2005;21:1683–1692.
- Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. *AIDS*. 2005;19:685–694.
- Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. *AIDS*. 2006;20:711–718.
- Soriano V, García-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. *J Antimicrob Chemother*. 2008;61:200–205.
- Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. *Clin Infect Dis*. 2007;44:1484–1492.
- Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. *JAMA*. 2006;296:806–814.
- Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the atazanavir-ritonavir monomaintenance (ATARITMO) trial. *AIDS*. 2007;21:1309–1315.
- Rodríguez-Novoa S, Morello J, Gonzalez M, et al. Increase in serum bilirubin in HIV/hepatitis C virus coinfecting patients on atazanavir therapy following initiation of pegylated interferon and ribavirin. *AIDS*. 2008;22:2535–2537.
- Busti A, Tsikouris J, Peeters M, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. *HIV Med*. 2006;7:317–322.
- Gallagher D, Kieran J, Sheehan G, et al. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. *Clin Infect Dis*. 2008;47:36–38.

35. Gianotti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. *AIDS*. 2007;21:1648–1651.
36. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. *J Acquir Immune Defic Syndr*. 2005;39:174–180.
37. Chang H, Pella P. Atazanavir urolithiasis. *N Engl J Med*. 2006;355:2158–2159.
38. Couzigou C, Daudon M, Meynard J, et al. Urolithiasis in HIV-positive patients treated with atazanavir. *Clin Infect Dis*. 2007;45:105–108.
39. Vora S, Marcellin AG, Gunthard H, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. *AIDS*. 2006;20(1):35–40.
40. Pellegrin I, Breilh D, Ragnaud JM, et al. Virological responses to atazanavir-ritonavir-based regimens: resistance substitutions score and pharmacokinetic parameters (Reyaphar study). *Antivir Ther*. 2006;11(4):421–429.
41. Bertoli A, Santoro MM, Lorenzini P, et al. Different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patients. *Antivir Ther*. 2006;11 Suppl 1:S99.

HIV/AIDS - Research and Palliative Care

Dovepress

Publish your work in this journal

HIV/AIDS - Research and Palliative Care is an international, peer-reviewed open-access journal focusing on advances in research in HIV, its clinical progression and management options including antiviral treatment, palliative care and public healthcare policies to control viral spread. The journal welcomes original research, basic science,

clinical & epidemiological studies, reviews & evaluations, expert opinion & commentary, case reports & extended reports. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/hiv-aids---research-and-palliative-care-journal>